These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 16861399

  • 21. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
    Sanz MJ, Cortijo J, Morcillo EJ.
    Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
    [Abstract] [Full Text] [Related]

  • 22. Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models.
    Yamamoto S, Sugahara S, Ikeda K, Shimizu Y.
    Eur J Pharmacol; 2006 Nov 21; 550(1-3):166-72. PubMed ID: 17010967
    [Abstract] [Full Text] [Related]

  • 23. The selective phosphodiesterase 4 inhibitor RP 73-401 reduced matrix metalloproteinase 9 activity and transforming growth factor-beta release during acute lung injury in mice: the role of the balance between Tumor necrosis factor-alpha and interleukin-10.
    Corbel M, Germain N, Lanchou J, Molet S, R e Silva PM, Martins MA, Boichot E, Lagente V.
    J Pharmacol Exp Ther; 2002 Apr 21; 301(1):258-65. PubMed ID: 11907182
    [Abstract] [Full Text] [Related]

  • 24. Pharmacology of a novel, orally active PDE4 inhibitor.
    Dastidar SG, Ray A, Shirumalla R, Rajagopal D, Chaudhary S, Nanda K, Sharma P, Seth MK, Balachandran S, Gupta N, Palle V.
    Pharmacology; 2009 Apr 21; 83(5):275-86. PubMed ID: 19321962
    [Abstract] [Full Text] [Related]

  • 25. Effects of the phosphodiesterase type 4 inhibitor roflumilast on early and late allergic response and airway hyperresponsiveness in Aspergillus-fumigatus-sensitized mice.
    Hoymann HG, Wollin L, Muller M, Korolewitz R, Krug N, Braun A, Beume R.
    Pharmacology; 2009 Apr 21; 83(3):188-95. PubMed ID: 19176983
    [Abstract] [Full Text] [Related]

  • 26. The phosphodiesterase type IV inhibitor cilomilast decreases pro-inflammatory cytokine production from primary bronchial epithelial cells in lung transplantation patients.
    Murphy DM, Ward C, Forrest IA, Pritchard G, Jones D, Stovold R, Fisher AJ, Cawston TE, Lordan JL, Corris PA.
    J Heart Lung Transplant; 2006 Dec 21; 25(12):1436-40. PubMed ID: 17178338
    [Abstract] [Full Text] [Related]

  • 27. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
    Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J.
    Respir Res; 2006 Jan 19; 7(1):9. PubMed ID: 16423283
    [Abstract] [Full Text] [Related]

  • 28. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
    Kubo S, Kobayashi M, Iwata M, Miyata K, Takahashi K, Shimizu Y.
    Int Immunopharmacol; 2012 Jan 19; 12(1):59-63. PubMed ID: 22041526
    [Abstract] [Full Text] [Related]

  • 29. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro.
    Jones NA, Boswell-Smith V, Lever R, Page CP.
    Pulm Pharmacol Ther; 2005 Jan 19; 18(2):93-101. PubMed ID: 15649851
    [Abstract] [Full Text] [Related]

  • 30. Effects of PDE4 inhibitors on lipopolysaccharide-induced priming of superoxide anion production from human mononuclear cells.
    Germain N, Corbel M, Belleguic C, Boichot E, Lagente V.
    Mediators Inflamm; 2001 Jun 19; 10(3):117-23. PubMed ID: 11545248
    [Abstract] [Full Text] [Related]

  • 31. In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration.
    Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C.
    J Pharmacol Exp Ther; 2003 Oct 19; 307(1):373-85. PubMed ID: 12944497
    [Abstract] [Full Text] [Related]

  • 32. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
    He W, Huang FC, Hanney B, Souness J, Miller B, Liang G, Mason J, Djuric S.
    J Med Chem; 1998 Oct 22; 41(22):4216-23. PubMed ID: 9784096
    [Abstract] [Full Text] [Related]

  • 33. Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.
    Sanz MJ, Cortijo J, Taha MA, Cerdá-Nicolás M, Schatton E, Burgbacher B, Klar J, Tenor H, Schudt C, Issekutz AC, Hatzelmann A, Morcillo EJ.
    Br J Pharmacol; 2007 Oct 22; 152(4):481-92. PubMed ID: 17704822
    [Abstract] [Full Text] [Related]

  • 34. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
    Miotla JM, Teixeira MM, Hellewell PG.
    Am J Respir Cell Mol Biol; 1998 Mar 22; 18(3):411-20. PubMed ID: 9490659
    [Abstract] [Full Text] [Related]

  • 35. Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha.
    Cottam HB, Shih H, Tehrani LR, Wasson DB, Carson DA.
    J Med Chem; 1996 Jan 05; 39(1):2-9. PubMed ID: 8568809
    [Abstract] [Full Text] [Related]

  • 36. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Antoniu SA.
    Curr Opin Investig Drugs; 2006 May 05; 7(5):412-7. PubMed ID: 16729716
    [Abstract] [Full Text] [Related]

  • 37. [Pharmacological profile of roflumilast].
    Cortijo Gimeno J, Morcillo Sánchez E.
    Arch Bronconeumol; 2010 Dec 05; 46 Suppl 10():19-24. PubMed ID: 21316552
    [Abstract] [Full Text] [Related]

  • 38. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
    Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W.
    J Clin Pharmacol; 2002 Mar 05; 42(3):297-303. PubMed ID: 11865966
    [Abstract] [Full Text] [Related]

  • 39. Roflumilast: a selective phosphodiesterase 4 inhibitor.
    Christie P.
    Drugs Today (Barc); 2005 Oct 05; 41(10):667-75. PubMed ID: 16389409
    [Abstract] [Full Text] [Related]

  • 40. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
    Konrad FM, Bury A, Schick MA, Ngamsri KC, Reutershan J.
    PLoS One; 2015 Oct 05; 10(4):e0121725. PubMed ID: 25909327
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.